Laureate Pharma, a biopharmaceutical development and protein production company, has entered into a current Good Manufacturing Products manufacturing contract agreement with fellow USA-based Tolera Therapeutics, a biotechnology company that develops and offers targeted therapies and safer solutions for immune modulation and related medical needs.
Laureate will produce Tolera's TOL101 monoclonal antibody under cGMP conditions to be used in clinical trials. Financial terms of the deal were not disclosed.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze